Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.)

AdipoGen Life Sciences

Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.)

10

Research Use Only

IL-1 is a group of inflammatory cytokines, represented by interleukin-1alpha and interleukin-1beta. IL-1Ra is a cytokine initially isolated from macrophages. It shares 19% of homologous amino acids with IL1A and 30% of homologous amino acids with IL1B. IL-1Ra is abundant in the proximal digestive tract reproductive system, skin, bone marrow, and liver. IL-1Ra is the principal endogenous IL-1 antagonist. IL-1Ra is upregulated during host acute or chronic inflammatory responses. IL-1Ra plays diverse roles in anti-inflammatory and anti-tumor processes, either inhibiting tumor angiogenesis and proliferation or suppressing tumor migration and metastasis. The protein Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.) is produced by using two different vectors, one encoding for the Fc Knobs (LALA-PG) (human):IL-1Ra (mouse) sequence (synthesizing a protein of 50kDa) and one encoding for the Fc Holes (LALA-PG) sequence (synthesizing a protein of 30kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.). This Fc-KIH format allows our mouse IL-1Ra protein to form a monomer that is the most active structure to bind and inhibit the IL-1 receptor. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences. - InVivoKines™. Recombinant Protein. The extracellular domain of mouse IL-1Ra (aa 27-178) is fused to the C-terminus of the Fc (LALA-PG) Knob region of human IgG1. Fc (LALA-PG) Knobs:IL-1Ra (mouse) and Fc (LALA-PG) Holes form the Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (rec.) using the Knobs-into-Holes technology (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). Source: HEK 293 cells. Produced using animal component-free medium.. It inhibits the binding of IL-1alpha and IL-1beta to the receptor IL-1R. The Fc contains the mutations LALA-PG that abolish the interaction between the Fc and FcgammaRs and therefore Fc undesirable effects. Lyophilized. Contains PBS IL-1 is a group of inflammatory cytokines, represented by interleukin-1alpha and interleukin-1beta. IL-1Ra is a cytokine initially isolated from macrophages. It shares 19% of homologous amino acids with IL1A and 30% of homologous amino acids with IL1B. IL-1Ra is abundant in the proximal digestive tract reproductive system, skin, bone marrow, and liver. IL-1Ra is the principal endogenous IL-1 antagonist. IL-1Ra is upregulated during host acute or chronic inflammatory responses. IL-1Ra plays diverse roles in anti-inflammatory and anti-tumor processes, either inhibiting tumor angiogenesis and proliferation or suppressing tumor migration and metastasis. The protein Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.) is produced by using two different vectors, one encoding for the Fc Knobs (LALA-PG) (human):IL-1Ra (mouse) sequence (synthesizing a protein of 50kDa) and one encoding for the Fc Holes (LALA-PG) sequence (synthesizing a protein of 30kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.). This Fc-KIH format allows our mouse IL-1Ra protein to form a monomer that is the most active structure to bind and inhibit the IL-1 receptor. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

-20°C,2°C to 8°C

12352204